pharma news today glp-1 obesity drugs today Market Size to Hit USD 132.79 Bn by 2035 GLP-1s and the Unintended Consequences
Description
GLP-1 agonists assist in weight loss by helping control overall calorie consumption
These agents benefit individuals with atherosclerosis, heart failure, or chronic kidney disease (CKD) (6)
Sustainable value chains and pricing insights are becoming key factors as payers focus on cost-effectiveness
This meta-analysis explored one in particular, that has a serious impact: Coenzyme Q10 (CoQ10) It analyzed 12 clinical trials involving 362 patients with hypertension
Most GLP-1 and dual GIP/GLP-1 agonists are injected
Without insurance, typical retail pricing for a 28day carton of Mounjaro (4 pens)
